The most read stories from across Cardiovascular News in March 2022 include a wealth of late-breaking research and clinical data from CRT 2022 (26 February–1 March, Washington DC, USA), research priorities for device-based therapies for hypertension, the use of deep learning in conjunction with coronary CT angiography, and interventional cardiologists bringing healthcare to children in some of the world’s most challenging regions.
- CRT 2022: SURPASS registry shows low rate of adverse events associated with Watchman FLX
Results from a new analysis assessing real-world outcomes with the Watchman FLX (Boston Scientific) left atrial appendage closure (LAAC) demonstrated a low rate of major adverse events at seven days following the procedure.
- CRT 2022: Novel transfemoral mitral valve repair technology wins innovation competition
A novel transcatheter system designed for transfemoral mitral valve repair—the NeoChord Nexus system—won the CRT Best Innovation Competition, taking place at the CRT 2022 annual meeting (26 February–1 March, Washington DC, USA).
- CRT 2022: Final BIOFLOW-V results “affirm durability” of Orsiro out to five years
Final five-year results from the BIOFLOW-V trial, presented during a late-breaking trial session at CRT 2022 (26 February–1 March, Washington DC, USA), affirm the durability of longer-term outcomes with the ultrathin Orsiro coronary drug-eluting stent (DES) compared to Xience (Abbott).
- CSI’s Propel pVAD system gets first-in-human use
Cardiovascular Systems—CSI—has announced the first in-human experience with Propel, its first-generation percutaneous ventricular assist device (pVAD), offering haemodynamic support for patients undergoing high-risk percutaneous coronary intervention (HR-PCI).
- First-in-human study paves way for further clinical trials of Valvosoft
Cardiawave has announced the success of its first-in-human I (FIH I) safety and feasibility clinical trial for Valvosoft its breakthrough technology that allows for the remote application of a focused therapeutic ultrasound beam to restore valve function in patients with aortic stenosis (AS).
- Expert group sets out principles for device-led hypertension trials
A consensus document outlining design principles and outcome definitions for device-based therapies for hypertension has been published in the journal Circulation.
- CRT 2022: Four-year LRT data “support TAVI in low-risk patients”
Four-year data from the LRT—Low Risk TAVR—trial show that transcatheter aortic valve implantation (TAVI) in low-risk patients with symptomatic severe aortic stenosis yields low adverse event rates and excellent haemodynamics, according to LRT principal investigator Ron Waksman (Medstar Washington Hospital Center, Washington DC, USA).
- Deep learning tool could predict future myocardial infarction
Researchers have detailed the use of an artificial intelligence-enabled tool for atherosclerotic plaque quantification from coronary CT angiography (CCTA), which they claim may make it easier to predict if a person will have a heart attack.
- CRT 2022: “Reassuring” two-year outcomes for bicuspid TAVI
Two-year findings from the Low-risk TAVI (LRT) Trial, assessing clinical outcomes after transcatheter aortic valve implantation (TAVI) in low-risk patients with symptomatic, severe bicuspid aortic stenosis have yielded “reassuring” results, attendees at CRT 2022 (26 February–1 March, Washington DC, USA) have heard.
- Cardiologists without borders
Interventional cardiologist Sagi Assa (Holon, Israel) talks to Cardiovascular News about his work with the humanitarian charity Save a Child’s Heart. The organisation offers treatment to children with congenital heart disease from some of the world’s most challenging regions, including Gaza and the West Bank.